Bone Biologics Co. (NASDAQ:BBLG) Sees Significant Decrease in Short Interest

Bone Biologics Co. (NASDAQ:BBLG) saw a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 76,500 shares, a decrease of 60.4% from the February 28th total of 193,300 shares. Based on an average trading volume of 211,100 shares, the days-to-cover ratio is presently 0.4 days. Currently, 14.3% of the company’s shares are short sold.

Bone Biologics Trading Down 1.5 %

Shares of BBLG stock opened at $0.85 on Thursday. Bone Biologics has a 1-year low of $0.71 and a 1-year high of $4.25. The firm’s 50-day simple moving average is $0.97 and its 200-day simple moving average is $1.24.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.